NewLink Ebola Shot Test Halted in Geneva on Side Effect
This article is for subscribers only.
A trial of NewLink Genetics Corp.’s experimental Ebola vaccine in Geneva will be suspended after four cases of mild joint pain in the hands and feet of healthy volunteers.
Vaccination will resume Jan. 5, allowing time for researchers to gather more information and share it with other teams that are testing the shot, according to a statement from University Hospitals of Geneva, which is overseeing the trial. Merck & Co. agreed last month to buy the rights to the vaccine and work with Ames, Iowa-based NewLink to develop it.